Form 4: Alnylam Pharmaceuticals Director Peter Kellogg Reports Stock and Option Awards

Director Peter Kellogg reports the acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• On May 8, 2025, Peter N. Kellogg, a director of Alnylam Pharmaceuticals, acquired 775 shares of common stock in the form of restricted stock units (RSUs) and an option to purchase 1,558 shares of common stock.
• The RSUs vest upon the earlier of the first anniversary of the grant date or the director's retirement or resignation, provided such retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• The stock option also vests under the same conditions as the RSUs and expires on May 8, 2035.
• The exercise price of the stock option is $258.35.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reports standard compensation practices, which are generally viewed favorably as they align director interests with shareholders.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions encourage continued service by the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This is a standard practice for compensating directors in publicly traded companies, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical industry.
• Companies like Moderna, BioNTech, and Regeneron also grant stock options and restricted stock units to their directors as part of their compensation packages.
• The vesting schedules and terms are generally comparable to industry norms, designed to incentivize long-term commitment and alignment with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term performance.
• Employees are not directly impacted by this filing.

Key Dates

Keywords

Alnylam Pharmaceuticals, Peter Kellogg, Director, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership